Cabazitaxel

證據等級: L5

預測適應症: 10 個

Cabazitaxel: From Prostate Cancer — Repurposing Evaluation (Predictions Pending)

One-Sentence Summary

Cabazitaxel (Jevtana®) is a semi-synthetic taxane derivative approved internationally for metastatic castration-resistant prostate cancer (mCRPC) after prior docetaxel-based therapy. This Evidence Pack does not yet contain TxGNN repurposing predictions — the prediction pipeline has not been completed due to unresolved data gaps (MOA and regulatory package insert). Without prediction outputs, no new indication can be evaluated at this time.

Quick Overview

Item	Content
Original Indication	Metastatic castration-resistant prostate cancer (mCRPC), second-line after docetaxel
Predicted New Indication	Not available — TxGNN predictions not yet generated
TxGNN Prediction Score	Not available
Evidence Level	L5 (model predictions not yet run)
Market Status	Not marketed in this jurisdiction
Number of Authorizations	0
Recommended Decision	Hold — complete data pipeline before assessment

Drug Background

Cabazitaxel is a microtubule-stabilising agent belonging to the taxane class. It was developed specifically to overcome resistance to docetaxel, as it shows low affinity for P-glycoprotein — the efflux pump responsible for taxane resistance in many tumour cell lines.

Its primary mechanism involves binding to tubulin and inhibiting microtubule depolymerisation, thereby arresting cell division at the G2/M phase. This mechanism is broadly applicable across tumour types that rely on rapid cell division, making it a candidate of interest for repurposing beyond prostate cancer.

Cabazitaxel is approved by the FDA (2010) and EMA (2011) under the brand name Jevtana® for mCRPC. It is not currently marketed in this jurisdiction (0 local authorizations), which means importation or local registration would be required for any clinical application.

Note on MOA data gap: The Evidence Pack lists MOA as a High-severity data gap (DG002). The background above is based on established pharmacological literature and should be formally confirmed via DrugBank API before proceeding to a full repurposing analysis.

Why No Repurposing Assessment is Possible Yet

The Evidence Pack is incomplete:

Data Gap	Severity	Impact
TFDA package insert (warnings/contraindications)	Blocking	Cannot complete S1 safety screening
Mechanism of action (MOA)	High	Cannot perform mechanistic similarity analysis
TxGNN prediction output	Critical	No new indication predicted — `predicted_indications: []`

The predicted_indications array is empty, which means either:

The TxGNN prediction step has not yet been run for this drug, or
The prediction pipeline was blocked by the upstream data gaps above.

Until TxGNN produces a ranked list of candidate indications, there is no repurposing target to evaluate.

Cytotoxicity

Cabazitaxel is a cytotoxic chemotherapy agent. The following applies regardless of repurposing target.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Taxane class
Myelosuppression Risk	High — Febrile neutropenia is the most common serious adverse event; G-CSF prophylaxis is standard of care
Emetogenicity Classification	Low to moderate
Monitoring Items	CBC with differential (weekly during first cycle), liver function, renal function, electrolytes
Handling Protection	Must follow cytotoxic drug handling regulations — closed-system transfer devices required

Safety Considerations

The Evidence Pack contains no actionable safety data for this drug in this jurisdiction. Before any clinical or regulatory work proceeds:

Please refer to the EMA SmPC (Jevtana®) and current TFDA package insert for complete warnings, contraindications, and drug interaction information. The most critical known risks are febrile neutropenia, severe hypersensitivity reactions, and gastrointestinal toxicity.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for Cabazitaxel is missing both its TxGNN repurposing predictions and the blocking safety data required for S1 screening. There is no new indication to evaluate, and no safety baseline to assess against.

To proceed, the following is needed:

Resolve DG001 (Blocking): Download and parse the TFDA package insert PDF to extract warnings and contraindications — required to unlock the S1 safety gate.
Resolve DG002 (High): Query DrugBank API for formal MOA data to enable mechanistic similarity analysis.
Re-run TxGNN prediction pipeline for DB06772 — the predicted_indications array must be populated before any repurposing evaluation can begin.
Review EMA SmPC for Jevtana® as a supplementary safety reference, given the drug is approved in Europe but not in this jurisdiction.
Once predictions are available, reassess evidence level and decision recommendation per standard L1–L5 criteria.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.